Differential brain atrophy and neurogenetic profiles in cognitively-defined Alzheimer's disease subgroups
Groot, C.; Grothe, M. J.; Mukherjee, S.; Jelistratova, I.; Jansen, I.; van Loenhoud, A. C.; Risacher, S. L.; Saykin, A. J.; Mac Donald, C. L.; Mez, J.; Trittschuh, E. H.; Gryglewski, G.; Lanzenberger, R.; Pijnenburg, Y. A. L.; Barkhof, F.; Scheltens, P.; van der Flier, W. M.; Crane, P. K.; Ossenkoppele, R.
Show abstract
Elucidating mechanisms underlying the clinical heterogeneity observed among individuals with Alzheimers disease (AD) is key to facilitate personalized treatments. We categorized 679 individuals with AD into subgroups based on a relative impairment in one cognitive domain (i.e. AD-Memory, AD-Executive-Functioning, AD-Language and AD-Visuospatial-Functioning). We compared atrophy patterns derived from MRI and identified patterns that closely matched the respective cognitive profiles, i.e. medial temporal lobe atrophy in AD-Memory, fronto-parietal in AD-Executive-Functioning, asymmetric left-temporal in AD-Language, and posterior in AD-Visuospatial-Functioning. We then determined spatial correlations between subgroup-specific atrophy and a transcriptomic atlas of gene expression, which revealed both shared (e.g. mitochondrial respiration and synaptic function/plasticity) and subgroup-specific (e.g. cell-cycle for AD-Memory, protein metabolism in AD-Language, and modification of gene expression in AD-Visuospatial-Functioning) biological pathways associated with each subgroups atrophy patterns. We conclude that cognitive heterogeneity in AD is related to neuroanatomical differences, and specific biological pathways may be involved in their emergence.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- White matter integrity and its association with amyloid-PET and serum NfL in healthy APOE4 homozygotes, heterozygotes and non-carries 95%
- Non-linear microglial, inflammatory and oligodendrocyte dynamics across stages of Alzheimer's disease 95%
- An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimers disease 95%
Similar papers in this journal
- Preliminary Validation of a Structural Magnetic Resonance Imaging Metric for Tracking Dementia-Related Neurodegeneration and Future Decline 97%
- White matter hyperintensities and neuropsychiatric symptoms in Alzheimer’s disease and mild cognitive impairment 96%
- Distinct and joint effects of low and high levels of Aβ and tau deposition on cortical thickness 95%
Similar papers in this journal
- Associations between Alzheimer’s disease polygenic risk scores and hippocampal subfield volumes in 17,161 UK Biobank participants 97%
- The spatial distribution of coupling between tau and neurodegeneration in amyloid-β positive mild cognitive impairment 97%
- Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer’s disease 96%
Similar papers in this journal
- APOE-ε 4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology 95%
- Gene module-trait network analysis uncovers cell type specific systems and genes relevant to Alzheimers Disease 94%
- Circular RNA detection identifies circPSEN1 alterations in brain specific to Autosomal Dominant Alzheimer Disease 94%
Similar papers in this journal
- Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi-Cohort Validation Against Biomarkers of Alzheimer’s Disease and Neurodegeneration stratified by sex 96%
- Neurophysiological trajectories in Alzheimer's disease progression 95%
- Nomograms of Human Hippocampal Volume Shifted by Polygenic Scores 94%